Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings results on Tuesday. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.49) by $9.10, Bloomberg Earnings reports. Neuralstem had a negative net margin of 191,652.16% and a negative return on equity of 425.79%.

Neuralstem (NASDAQ:CUR) traded down 3.57% during midday trading on Wednesday, reaching $1.08. 429,157 shares of the company’s stock were exchanged. The stock’s market cap is $12.85 million. Neuralstem has a 12 month low of $1.03 and a 12 month high of $6.60. The firm has a 50 day moving average of $4.95 and a 200-day moving average of $4.57.

Separately, ValuEngine lowered shares of Neuralstem from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th.

In other Neuralstem news, CEO Richard J. Daly purchased 7,500 shares of Neuralstem stock in a transaction on Wednesday, May 17th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the chief executive officer now directly owns 23,312 shares of the company’s stock, valued at $93,248. The purchase was disclosed in a filing with the SEC, which is available at this link. 15.43% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Neuralstem, Inc. (NASDAQ:CUR) Posts Quarterly Earnings Results, Beats Expectations By $9.10 EPS” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/09/neuralstem-inc-nasdaqcur-posts-quarterly-earnings-results-beats-expectations-by-9-10-eps.html.

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Earnings History for Neuralstem (NASDAQ:CUR)

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.